With a prediction of about 20 million cases and 10 million deaths occurring to 2020, cancer is becoming one of the most important challenges in the field of human health. National Cancer Control plans are effective tools to set up actions that, by their specificity in regard to the local epidemiology and resources, can break the rising curve of human toll that we are paying to this disease. In this article we present the French experience with the National Cancer Plans. We point out the most significant actions that were developed in the areas of prevention, screening, care, access to innovative treatments, and research.
W ith a prediction of about 20 million cases and 10 million deaths occurring to 2020, cancer is becoming one of the most important challenges in the fıeld of human health. 1 By itself, cancer kills more human beings every year than tuberculosis, AIDS, and malaria altogether! 2 Even more in its declaration, the World Health Organization states that 75% of these expected deaths will occur in countries that together produce today less than 5% of the world GDP, which is really threatening. 3 Something has to be done in our developed countries as well as in low-and middle-income counties to try to control the development of these diseases.
National Cancer Control plans are effective tools to raise awareness of cancer and set up actions that, by their specifıc-ity in regards of the local epidemiology and resources, can break the rising curve of human toll we are paying to this disease.
A National Cancer Control plan is a set of proposed actions, based on the evaluated needs, issues, and strengths and weaknesses of a given country, that are aimed at declaring a global "war on cancer" using all available resources and knowledge to control cancer through coordinated , evaluated, and founded measures on prevention, screening, early diagnosis, access to quality care including in a palliative setting and end-of-life care, research, social action, and cooperation. Based on the charter of Paris against cancer, signed on After six months of offıcial hearings where all stakeholders were able to express their experience/thoughts/needs, a set of 71 measures was approved in March 2003-one of them being the creation of the French National Cancer Institute. 5 These actions concerned screening (13%), care and patient support (21%), access to innovative treatments (32%), and research and training (18%). [6] [7] A total budget of 1.7 billion euros was attributed to this plan to be spent over 4 years. A total of 3,900 new jobs were created.
Many signifıcant actions that were developed; some of them deserve to be pointed out:
PREVENTION
Several measures were taken in the fıeld of antitobacco regulation, such as a law voted on by the parliament to ban smoking in public places, the prohibition of selling tobacco to individuals age 16 or less, and the rapid rise (within less than 2 years) of the price of a packet of cigarettes from 3 to 5 euros, leading to a fırst ever achieved drop in the number of smokers in France. 8
SCREENING
We set up two nationally organized, controlled, and funded programs of breast and colorectal cancer screening.
The fırst one, concerning women age 49 to 74, was based on an invitation every two years to get a mammogram in controlled centers with a double reading. This needed evaluation of thousands of radiologic centers, an upgrade of the radiologists and their equipment, the organization of an effıcient circuit for the double reading, and the setup of good clinical practices for the actions that had to be taken in case of suspect image.
For colorectal screening, men and women age 49 to 74 were invited to do an hemocult test and send the results to their general practicioner who, in case of positivity, had to prescribe a colonoscopy.
The two national screening program were effective in 2006, at a time when France was noted as the only country having such a double program. 7
CARE
Two very signifıcant measures were taken in this fıeld.
The fırst one was the mandatory organization of a multidisciplinary concertation meeting in each institution where patients could be treated. The meetings required all cases to be discussed for the optimal management strategy between at least three oncologists and organ specialists (surgeon, radiotherapist, medical oncologist, etc.). The decision taken had to be explained to the patient and be reported in a computerized system in order to guarantee the best and the most updated approach to each patient with cancer. Remote hospitals were fully equipped with videoconference facilities and small center were fırmly incited to organize such multidisciplinary concentration meeting in a common way.
The second action declared by state law was that all institutions that were willing to treat patients with cancer had to apply for a 4-year renewable authorization based on a minimum number of each type of cancer they were treating and the guarantee of the quality of the cancer care they were providing.
A very signifıcant number of hospitals, private and public, were then unauthorized to continue to treat patients with cancer, raising the quality of the management of these patients in France. "This decision did causes a huge outery from thoses hospital "forbiden" to see patients with cancer.
As the president of the French NCI, I had to explain the rationale for such decision and get the support of the patient's organizations."
ACCESS TO INNOVATIVE TREATMENTS
In 2003, just before the onset of the national cancer plan, France spent only 335 million euros for the access to the newest therapies in cancer.
The limitation was a result of all public hospitals being fı-nanced by a yearly budget, disconnected with the need for newer, more expensive drugs and with no relationship between the budget for cancer and the number of patients with cancer.
The government decided to consider the new innovative anticancer medicines taken out of the general budget of the hospital, and in 2004 started to cover the hospital expenses on these drugs for each euro spent, therefore improving patient access to the drugs. The demonstration of the real need for an increased budget appeared rapidly as the total national expenditures on these medicines immediately increased to 1,038 million euro in 2009.
RESEARCH
Research units were forced to merge and commonly defıne a limited number of research topics that they could claim expertise. These new, much bigger, evaluated research organizations were called Cancéropôle, and seven of them were created covering all the national territory.
An extra state budget, based on requests for proposals that internationally evaluated in the most possible independent way, was then attributed to these Cancéropôle.
A total of 25% more money was given to cancer research compared with the total state budget spent yearly on it before the national plan, representing a very signifıcant and incitive increase, stimulating research units to merge and cooperate.
These are a few of the actions that were taken during the four years of the plan: 7 The lessons that we learned from the plan include the necessity, unusual for France before the plan, to coordinate all actors, including patient advocacy groups, to evaluate independently the projects and the results achieved. It is also a necessity to concentrate the care, at least for the defınition of the strategies, to centers that are fully certifıed to treat patients with cancer, even though treatments such as chemotherapy could be given in a small community canters in the vicinity of the patients.
Dealing with all these issues, moreover at once and within a relatively short time, France has shown itself as a political leader, and not only in health care reform. We have demonstrated the importance of our ability to increase the political awareness of cancer, and help our political representatives to consider a disease that effects almost one out of two men and one out of three women, is the leading cause of death, and more importantly, the leading cause of premature death, is not just "another disease," but also a political challenge.
KEY POINTS
⅐ National Cancer Plans are effective tools to fight against cancer. ⅐ Large hearings of all stakeholders skould be organized before drawing the plan. ⅐ The French National Cancer Plan (2003) (2004) (2005) (2006) was very efficient and dealt with all aspects of cancer control. ⅐ More international cooperation is needed to prepare lowand middle-income countries for their upcoming "epidemy" of cancer (WHO). ⅐ Cancer is not just "another disease" but also a political issue because of its massive economic and social impact.
